Nasus Pharma's research abstracts were accepted for a conference, but the announcement gives no study results. It adds visibility, not evidence of a change in the company's prospects.
This gives the treatment more attention among allergy specialists. But the announcement gives no study results or approval, so it does not show that the powder works or is closer to reaching patients.
Follow Nasus Pharma (NSRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NSRX